STK11 and lung carcinoma: However, a different study revealed that combining CB839 with anti-PD-1 treatment inhibited the clonal expansion and activation of CD8 + T cells in KEAP1 and STK11 double-mutant lung cancer, resulting in a loss of therapeutic benefit [37].